BackSHL Telemedicine Overview

SHL Telemedicine Net Income

Track SHL Telemedicine's net income ($-33M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$24.09M
↓ 396.04% YoY

As of Dec 2024

Annual Net Income (TTM)

-$32.95M
↓ 465.89% YoY

Trailing 12 months ending Dec 2024

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

SHL Telemedicine (SHLT) FAQ

The latest net income for SHLT is $-33M as of December 2024. That compares with $-5.8M in the prior-year period — down 465.9% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside SHL Telemedicine's historical trend and sector peers before judging valuation or financial health.

Over the past year, SHLT's net income moved from $-5.8M to $-33M — a 465.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SHL Telemedicine's operating scale or balance-sheet position.

Against Healthcare companies, SHLT currently prints $-33M for net income, while the sector average sits near $16B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at SHL Telemedicine's growth, margins, and balance sheet.

A net income figure of $-33M for SHLT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting SHLT's net income ($-33M), review year-over-year change from $-5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.